drugset
drugset / Trial / NCT04537897

A Study in Healthy Men and Women Who Are Either Between 18 - 45 Years or Between 65 - 80 Years to Test How Different Doses of BI 474121 Are Tolerated

NCT04537897 ↗

Phase 1 Completed 70 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The main objectives of this trial are to investigate safety and tolerability of BI 474121 in healthy male and female young and elderly subjects following oral administration of multiple rising doses per day over 14 days.

Timeline

Start
2020-10-06
Primary completion
2021-10-07
Completion
2021-10-07

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 474121 Unknown 2.5 mg Oral
Subject BI 474121 Unknown 5 mg Oral
Subject BI 474121 Unknown 10 mg Oral
Subject BI 474121 Unknown 20 mg Oral
Subject BI 474121 Unknown 30 mg Oral
Subject Midazolam Small molecule 75 ug Oral

Indications

No indication recorded.